# Respirent Pharmaceuticals Co Ltd. clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Respirent Pharmaceuticals Co Ltd. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Respirent Pharmaceuticals Co Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/respirent-pharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 6, 2023 | NCT06025214 | Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06025214) |
| August 9, 2023 | NCT05982990 | Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05982990) |
| January 25, 2023 | NCT05697003 | Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05697003) |
| December 23, 2022 | NCT05664061 | Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent... | Respirent Pharmaceuticals Co Ltd. | Phase 3 | Unknown | Asthma | 451 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05664061) |
| May 31, 2022 | NCT05397834 | A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS®... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Asthma, Bioequivalence | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05397834) |
| October 20, 2021 | NCT05085587 | Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs.... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Bioequivalence, Asthma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05085587) |
| August 26, 2021 | NCT05021887 | A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS®... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Asthma, Bioequivalence | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05021887) |
| March 10, 2021 | NCT04790838 | Pooled Analysis FP\_SX\_250\_50 | Respirent Pharmaceuticals Co Ltd. | Observational | Completed | Asthma | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04790838) |
| February 9, 2021 | NCT04746040 | A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Unknown | Bioequivalence, Asthma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04746040) |
| December 14, 2020 | NCT04665895 | A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent... | Respirent Pharmaceuticals Co Ltd. | Phase 3 | Completed | Asthma | 451 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04665895) |
| September 25, 2020 | NCT04564456 | A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04564456) |
| September 11, 2020 | NCT04546256 | A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04546256) |
| July 10, 2020 | NCT04466176 | A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04466176) |
| July 8, 2020 | NCT04462822 | A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04462822) |
| October 11, 2019 | NCT04124094 | A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04124094) |
| June 5, 2019 | NCT03975166 | A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03975166) |
| March 28, 2019 | NCT03894280 | A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03894280) |
| January 29, 2019 | NCT03820180 | A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals... | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03820180) |
| November 23, 2018 | NCT03751202 | A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers | Respirent Pharmaceuticals Co Ltd. | Phase 1 | Completed | Bioequivalence | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03751202) |
| September 18, 2018 | NCT03676413 | A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation... | Respirent Pharmaceuticals Co Ltd. | Phase 3 | Completed | Asthma | 451 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03676413) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 3 | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Unknown | 8 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Asthma | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Backflow companies in the United States](https://specstream.ai/data/businesses/backflow-companies/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Internal medicine practices in the United States](https://specstream.ai/data/businesses/internal-medicine-practices/united-states)
